Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients

被引:4
|
作者
Volteas, Panagiotis [1 ]
Drakos, Panagiotis [1 ]
Alkadaa, Leor N. [2 ]
Cleri, Nathaniel A. [2 ]
Asencio, Anthony A. [2 ]
Oganov, Anthony [2 ]
Giannopoulos, Stefanos [1 ,3 ]
Saadon, Jordan R. [2 ]
Mikell, Charles B., III [2 ]
Rubano, Jerry A. [1 ]
Labropoulos, Nicos [3 ]
Tassiopoulos, Apostolos K. [1 ,3 ]
Mofakham, Sima [2 ]
Bannazadeh, Mohsen [1 ,3 ]
机构
[1] Renaissance Sch Med, Dept Surg, Stony Brook, NY USA
[2] Renaissance Sch Med, Dept Neurosurg, Stony Brook, NY USA
[3] Renaissance Sch Med, Div Vasc Surg, Dept Surg, Stony Brook, NY USA
关键词
COVID-19; SARS-CoV-2; Low-molecular-weight heparin (LMWH); Unfractionated heparin (UFH); Thromboprophylaxis; Anticoagulation (AC); ANTICOAGULATION; ENOXAPARIN;
D O I
10.1016/j.jvsv.2022.04.019
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Thrombosis in COVID-19 worsens mortality. In our study, we sought to investigate how the dose and type of anticoagulation (AC) can influence patient outcomes. Methods: This is a single-center retrospective analysis of critically ill intubated patients with COVID-19, comparing low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH) at therapeutic and prophylactic doses. Of 218 patients, 135 received LMWH (70 prophylactic, 65 therapeutic) and 83 UFH (11 prophylactic, 72 therapeutic). The primary outcome was mortality. Secondary outcomes were thromboembolic complications confirmed on imaging and major bleeding complications. Cox proportional-hazards regression models were used to determine whether the type and dose of AC were independent predictors of survival. We performed Kaplan-Meier survival analysis to compare the cumulative survivals. Results: Overall, therapeutic AC, with either LMWH (65% vs 79%, P = .09) or UFH (32% vs 46%, P = .73), conveyed no survival benefit over prophylactic AC. UFH was associated with a higher mortality rate than LMWH (66% vs 28%, P= .001), which was also evident in the multivariable analysis (LMWH vs UFH mortality, hazard ratio: 0.47, P = .001) and in the Kaplan-Meier survival analysis. Thrombotic and bleeding complications did not depend on the AC type (prophylactic LMWH vs UFH: thrombosis P = .49, bleeding P = .075; therapeutic LMWH vs UFH: thrombosis P = .5, bleeding P = .17). When comparing prophylactic with therapeutic AC, the rate of both thrombotic and bleeding complications was higher with the use of LMWH compared with UFH. In addition, transfusion requirements were significantly higher with both therapeutic LMWH and UFH. Conclusions: Among intubated critically ill COVID-19 intensive care unit patients, therapeutic AC, with either LMWH or UFH, conveyed no survival benefit over prophylactic AC. AC with LMWH was associated with higher cumulative survival compared with AC with UFH.
引用
收藏
页码:1128 / 1136
页数:9
相关论文
共 50 条
  • [1] Low-Molecular-Weight Heparin Resistance and Its Viscoelastic Assessment in Critically Ill COVID-19 Patients
    Boesch, Johannes
    Rugg, Christopher
    Schaefer, Volker
    Lichtenberger, Philipp
    Staier, Nikolai
    Treichl, Benjamin
    Rajsic, Sasa
    Peer, Andreas
    Schobersberger, Wolfgang
    Fries, Dietmar
    Bachler, Mirjam
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2022, 48 (07): : 850 - 857
  • [2] Thromboprophylaxis in the critically Ill Low Molecular Weight Heparin versus unfractionated Heparin
    Petros, S.
    [J]. MEDIZINISCHE KLINIK-INTENSIVMEDIZIN UND NOTFALLMEDIZIN, 2016, 111 (01) : 55 - 56
  • [3] Use of low-molecular-weight heparin in COVID-19 patients
    Kow, Chia Siang
    Hasan, Syed Shahzad
    [J]. JOURNAL OF VASCULAR SURGERY-VENOUS AND LYMPHATIC DISORDERS, 2020, 8 (05) : 900 - 901
  • [4] Unfractionated heparin or low-molecular-weight heparin in the elderly
    Dorobantu, Maria
    Bogdan, Stefan
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 222 : 1084 - 1090
  • [5] PHARMACOKINETICS OF UNFRACTIONATED HEPARIN AND OF LOW-MOLECULAR-WEIGHT HEPARIN
    BONEU, B
    [J]. THROMBOSIS AND HAEMOSTASIS, 1991, 65 (06) : 872 - 872
  • [6] Unfractionated heparin compared with low-molecular-weight heparin as related to heparin-induced thrombocytopenia
    Walenga, JM
    Prechel, M
    Jeske, WP
    Bakhos, M
    [J]. CURRENT OPINION IN PULMONARY MEDICINE, 2005, 11 (05) : 385 - 391
  • [7] COVID-19, Low-Molecular-Weight Heparin, and Hemodialysis
    Perna, Alessandra F.
    Capolongo, Giovanna
    Trepiccione, Francesco
    Simeoni, Mariadelina
    Zacchia, Miriam
    Ingrosso, Diego
    [J]. KIDNEY & BLOOD PRESSURE RESEARCH, 2020, 45 (03): : 357 - 362
  • [8] Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer
    Van Matre, E. T.
    Reynolds, P. M.
    MacLaren, R.
    Mueller, S. W.
    Wright, G. C.
    Moss, M.
    Burnham, E. L.
    Ho, P. M.
    Vandivier, R. W.
    Kiser, T. H.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2018, 16 (12) : 2492 - 2500
  • [9] Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery
    De, Anushtup
    Roy, Prabal
    Garg, Vinod K.
    Pandey, Narendra K.
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 2010, 21 (01) : 57 - 61
  • [10] Spontaneous Hematomas in COVID-19 Patients on Low-Molecular-Weight Heparin
    Taleja, Hitesh
    Nair, Vipin Venugopal
    Yadav, Sunanda
    Venkatnarayanan, Raghavendra
    Roy, Nilanjan
    Rao, Pankaj
    [J]. DUBAI MEDICAL JOURNAL, 2021, 4 (03): : 285 - 290